Nkarta Announces Leadership Changes
05 Octubre 2020 - 3:02PM
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical
company developing engineered natural killer (NK) cell therapies to
treat cancer, today announced that Nadir Mahmood, Ph.D., Chief
Business Officer of Nkarta, is assuming the expanded role of Chief
Financial and Business Officer effective immediately. He replaces
Matthew Plunkett, Ph.D. who has stepped down as Chief Financial
Officer to pursue other opportunities. In addition, Alicia J.
Hager, J.D., Ph.D. is expected to join Nkarta as Chief Legal
Officer later this month.
“We are delighted to welcome Nadir to his newly expanded role at
Nkarta,” said Paul J. Hastings, Chief Executive Officer of Nkarta.
“Since joining the company in 2018, Nadir has played a direct role
in shaping Nkarta’s strategy and operations, provided exceptional
cross-functional leadership and demonstrated a deep understanding
of the many facets of our business. These achievements, in addition
to his experience in corporate development and equity research,
make him particularly well suited for Nkarta at this stage in our
growth. He will be supported by a seasoned finance organization as
we look forward to his continued contributions.”
Mahmood said, “I look forward to working with our investors,
collaborators and the Nkarta team as we continue the important
pursuit of advancing the next potential wave of transformative cell
therapy that can bring new hope to cancer patients. Building on the
strong foundation Matt helped to create, we remain focused on
expanding platform innovation, advancing our manufacturing
capabilities, and preparing for clinical trials of our potentially
disruptive co-lead NK cell therapy candidates.”
Hastings continued, “We would like to thank Matt for his many
valuable contributions to Nkarta. His unique skill set of advanced
scientific training and financial market experience helped us
rapidly build our financial foundation and take Nkarta to where we
are today. I know I speak for everyone at the company when I say we
wish Matt well as he embarks on the next leg of his successful
career.”
Plunkett added, “I appreciate the opportunity from Paul and the
Board to contribute to Nkarta’s financing and operations over the
last two years, and I am delighted to leave the company with a
solid financial foundation for future success.”
“We’re also pleased to welcome Alicia to Nkarta as we broaden
the expertise and capabilities of our outstanding leadership team,”
Hastings added. “As an experienced chief counsel and biopharma
executive, she will provide critical legal expertise and leadership
to support our goal of accelerating the development of
groundbreaking therapies.”
About Nadir Mahmood, Ph.D.Prior to joining
Nkarta in 2018, Dr. Mahmood headed corporate development at Second
Genome where he was responsible for establishing strategy and
partnerships across the company’s portfolio of programs. Earlier in
his career, he was staff scientist at Kythera Biopharmaceuticals
(acquired by Allergan), overseeing preclinical research for the
company’s lead molecule, Kybella®. Dr. Mahmood has also worked in
equity research at Goldman Sachs and consulted for early stage
companies in the life sciences and clean energy sectors. He earned
a B.S. in Biochemistry from the University of Texas at Austin and a
Ph.D. in Cell Regulation from the University of Texas Southwestern
Medical Center, and completed postdoctoral research at the Scripps
Research Institute in La Jolla, CA.
About Alicia J.
Hager, J.D.,
Ph.D.Dr. Hager brings to Nkarta a deep scientific
background and nearly 20 years of broad legal experience in the
life sciences. She previously served as Senior Vice President and
General Counsel of OncoMed Pharmaceuticals, where she held multiple
roles of increasing responsibility and leadership over the years.
Prior to joining OncoMed, Dr. Hager was an attorney at the law firm
of Morrison & Foerster LLP, where she served as intellectual
property counsel for biotech and pharmaceutical clients. Earlier in
her career, Dr. Hager was a patent agent at the law firm of Heller
Ehrman White & McAuliffe LLP. Dr. Hager received an A.B. in
Chemistry from Occidental College, an A.M. and Ph.D. in Chemistry
from Harvard University and a J.D. from Stanford Law School.
About NkartaNkarta is a clinical-stage
biotechnology company advancing the development of allogeneic
natural killer (NK) cell therapies for cancer. By combining its
cell expansion and cryopreservation platform with proprietary cell
engineering technologies, Nkarta is building a pipeline of cell
therapy candidates generated by efficient manufacturing processes,
and engineered to enhance tumor targeting and improve persistence
for sustained activity in the body. For more information, please
visit the company’s website at www.nkartatx.com.
Cautionary Note on Forward-Looking Statements
Statements contained in this press release regarding matters that
are not historical facts are “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Words such as "anticipates," "believes,"
"expects," "intends," “plans,” “potential,” "projects,” “would” and
"future" or similar expressions are intended to identify
forward-looking statements. Examples of these forward-looking
statements include statements concerning: Nkarta’s expectations
regarding its growth and financial position, the progress of its
platform innovation and manufacturing capabilities, and the
expertise of its executives. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
These risks and uncertainties are described more fully in Nkarta’s
filings with the Securities and Exchange
Commission (“SEC”), including the “Risk Factors” section of
the Company’s Quarterly Report on Form 10-Q for the quarterly
period ended June 30, 2020, filed with
the SEC on August 20, 2020, and our other documents
subsequently filed with or furnished to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, Nkarta undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Nkarta Media/Investor Contact:Greg MannNkarta,
Inc.gmann@nkartatx.com
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024